David Kirn
2023
In 2023, David Kirn earned a total compensation of $10.3M as Chief Executive Officer at 4D Molecular Therapeutics, a 213% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $394,953 |
|---|---|
| Option Awards | $9,278,715 |
| Salary | $596,640 |
| Other | $16,500 |
| Total | $10,286,808 |
Kirn received $9.3M in option awards, accounting for 90% of the total pay in 2023.
Kirn also received $395K in non-equity incentive plan, $596.6K in salary and $16.5K in other compensation.
Rankings
In 2023, David Kirn's compensation ranked 22nd out of 2,268 executives tracked by ExecPay. In other words, Kirn earned more than 99.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 22 out of 2,268 | 99th |
Division Manufacturing | 8 out of 1,238 | 99th |
Major group Chemicals And Allied Products | 5 out of 696 | 99th |
Industry group Drugs | 5 out of 667 | 99th |
Industry Biological Products, Except Diagnostic Substances | 2 out of 162 | 99th |
Source: SEC filing on April 10, 2024.
Kirn's colleagues
We found two more compensation records of executives who worked with David Kirn at 4D Molecular Therapeutics in 2023.
News
4D Molecular Therapeutics CEO David Kirn's 2023 pay jumps 213% to $10M
April 10, 2024
4D Molecular Therapeutics CEO David Kirn's 2022 pay falls 37% to $3.3M
April 12, 2023
4D Molecular Therapeutics CEO David Kirn's 2021 pay jumps 641% to $5.2M
April 13, 2022
4D Molecular Therapeutics Chief Medical Officer Robert Fishman receives $3.3M in 2020
April 6, 2021